Eagle Pharmaceuticals’ (EGRX) “Underperform” Rating Reaffirmed at Mizuho
Eagle Pharmaceuticals (NASDAQ:EGRX)‘s stock had its “underperform” rating reiterated by analysts at Mizuho in a research note issued to investors on Wednesday, MarketBeat Ratings reports. They presently have a $40.00 price objective on the specialty pharmaceutical company’s stock, up from their prior price objective of $37.00. Mizuho’s price target would suggest a potential downside of 26.58% from the stock’s current price.
A number of other equities research analysts have also issued reports on EGRX. BidaskClub raised Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, December 2nd. ValuEngine lowered Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Zacks Investment Research lowered Eagle Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 9th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $79.00 target price on shares of Eagle Pharmaceuticals in a research report on Tuesday, January 30th. Finally, Royal Bank of Canada set a $71.00 target price on Eagle Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, February 26th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $63.33.
Shares of EGRX stock traded up $0.28 during trading on Wednesday, hitting $54.48. The stock had a trading volume of 50,434 shares, compared to its average volume of 251,731. The firm has a market capitalization of $778.47, a price-to-earnings ratio of 16.54 and a beta of 1.32. The company has a quick ratio of 3.88, a current ratio of 3.99 and a debt-to-equity ratio of 0.24. Eagle Pharmaceuticals has a 12 month low of $45.05 and a 12 month high of $97.15.
In related news, Director Sander A. Flaum sold 2,340 shares of the company’s stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $53.94, for a total transaction of $126,219.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 19.50% of the stock is currently owned by insiders.
A number of large investors have recently bought and sold shares of EGRX. Smith Asset Management Group LP acquired a new position in Eagle Pharmaceuticals during the fourth quarter valued at $187,000. Municipal Employees Retirement System of Michigan raised its position in Eagle Pharmaceuticals by 68.1% during the third quarter. Municipal Employees Retirement System of Michigan now owns 3,210 shares of the specialty pharmaceutical company’s stock valued at $191,000 after buying an additional 1,300 shares during the period. Campbell Newman Asset Management Inc. acquired a new position in Eagle Pharmaceuticals during the fourth quarter valued at $200,000. MetLife Investment Advisors LLC acquired a new position in Eagle Pharmaceuticals during the fourth quarter valued at $218,000. Finally, Schroder Investment Management Group acquired a new position in Eagle Pharmaceuticals during the third quarter valued at $219,000.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.